ÃÖ½Å³í¹®¸®ºä
   
Diabetic Foot Ulcers in Geriatric Patients
±Û¾´ÀÌ : °ü¸®ÀÚ ³¯Â¥ : 2025-04-16 (¼ö) 10:49 Á¶È¸ : 39
Á¶Èñ°æ_´ç´¢¹ß.docx (70.2K), Down : 0, 2025-04-16 10:49:08

Diabetic Foot Ulcers in Geriatric Patients

Arthur Stone, Cornelius Michael Donohue

Clin Geriatr Med 40 (2024) 437–447 doi: 10.1016/j.cger.2024.03.002.

INTRODUCTION

 °í·É ȯÀÚ¿¡¼­ ´ç´¢¹ß ±Ë¾ç(Diabetic Foot Ulcers, DFU) °ü¸®´Â Ãß°¡ÀûÀÎ µµÀü °úÁ¦¸¦ µ¿¹ÝÇÑ´Ù. ÀÌ´Â ³ë¼è(frailty)¿Í ±Ù°¨¼ÒÁõ(sarcopenia)À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ÀÇÇÐÀû ¹× ±â´ÉÀû µ¿¹Ý ÁúȯÀÌ »óó Ä¡À¯¿¡ ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®ÀÌ´Ù. º» ³í¹®Àº ´ç´¢¹ß ±Ë¾ç()ÀÇ º´Å»ý¸®, ¿¹¹æ ¹× Ä¡·á(ÀÇÇÐÀû ¹× ¿Ü°úÀû Ãø¸é)¸¦ °ËÅäÇÏ¿´°í, ü°èÀûÀÎ Áø´Ü ¹× Ä¡·á Á¢±Ù¹ýÀÇ Á߿伺°ú ÆÀ Á¢±Ù¹ý(team approach)ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ´Ù. ¶ÇÇÑ, ÀçȰ ¹× Àç¹ß ¹æÁö¸¦ Æ÷ÇÔÇÏ¿© ÃÖÀûÀÇ Ä¡·á °á°ú¸¦ ¾ò±â À§Çؼ­´Â °³Àκ° Ä¡À¯ °èȹ(Plan for Healing)À» ¼³°èÇÏ´Â °ÍÀÌ ÇʼöÀûÀÓÀ» ¾ð±ÞÇϰí ÀÖ´Ù.

ACUTE AND CHRONIC WOUNDS

 Á¤»óÀûÀÎ Ä¡À¯ °úÁ¤À» °ÅÄ¡Áö ¸øÇϰí 1°³¿ù ÀÌ»ó Ä¡À¯µÇÁö ¾Ê´Â »óó´Â ¸¸¼º »óó(chronic wound)·Î ºÐ·ùµÈ´Ù. ƯÈ÷ ´ç´¢º´°ú ºñ¸¸À» °¡Áø ȯÀÚ´Â ¸¸¼º »óó°¡ ¹ß»ýÇÒ À§ÇèÀÌ ³ô´Ù. ´ç´¢¹ß ±Ë¾ç ¹× ±âŸ »óóÀÇ Ä¡À¯ °á°ú¿¡ Áß¿äÇÑ ¿ä¼Ò´Â Á¶±â Áø´Ü°ú Ä¡·áÀÇ Á¶±â ½ÃÀÛÀÌ´Ù. À̸¦ ÅëÇØ »ýÁ¸ °¡´ÉÇÑ Á¶Á÷(viable tissue)ÀÇ À¯Áö ¹× º¸Çà ±â´É(ambulatory function)À» ÃÖÀûÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¿¬ºÎÁ¶Á÷ ¹× °ñÁ¶Á÷¿¡¼­ÀÇ °¨¿°°ú ¾ÇÈ­¸¦ ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ¸¸¾à ¾ÇÈ­°¡ ÁøÇàµÉ °æ¿ì¿¡´Â Àý´Ü(amputation) ¹× ÆÐÇ÷Áõ(sepsis)À¸·Î ÀÎÇÑ »ç¸Á À§ÇèÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Ù.

EPIDEMIOLOGY OF DIABETIC FOOT ULCERS

 ´ç´¢¹ß ±Ë¾çÀº Àå±â°£ Á¶ÀýµÇÁö ¾ÊÀº ´ç´¢º´À¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ½É°¢Çϰí Àç¹ß °¡´É¼ºÀÌ ³ôÀº ÁúȯÀ¸·Î ÀϹÝÀûÀ¸·Î ¹ß¹Ù´Ú¿¡ ±Ë¾ç(ulceration) ÇüÅ·Π³ªÅ¸³­´Ù. ´ç´¢¹ß ±Ë¾çÀÇ º´¸®ÇÐÀû ±âÀüÀº ´ÙÀ½°ú °°Àº 3 °¡Áö ÁÖ¿ä ¿äÀÎ(triad)À¸·Î ±¸¼ºµÈ´Ù.
  • 1). ½Å°æº´Áõ(neuropathy)
  • 2). Ç÷°ü ºÎÀü(vascular insufficiency)
  • 3). ¹ß ¿Ü»ó ÈÄ ÀÌÂ÷ °¨¿°(secondary infection after trauma to the foot)
 ±¹Á¦´ç´¢º´¿¬¸Í(International Diabetes Foundation)¿¡ µû¸£¸é,Àü ¼¼°è DFUȯÀÚ´Â 4,000¸¸~6,000¸¸ ¸íÀ¸·Î, 2015³â ÃßÁ¤Ä¡(900¸¸~2,600¸¸ ¸í)¿¡¼­ Å©°Ô Áõ°¡Çß´Ù. ÃÖ±Ù ¸ÞŸ ºÐ¼®¿¡ µû¸£¸é ´ç´¢º´ ȯÀÚÀÇ 6.3%°¡ DFU¸¦ °æÇèÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ¾à 3,300¸¸ ¸í¿¡ ÇØ´çÇÑ´Ù. Á¦1Çü ´ç´¢º´(T1D)º¸´Ù Á¦2Çü ´ç´¢º´(T2D)¿¡¼­ DFUÀÇ À¯º´·üÀÌ ³ô´Ù.

DIABETIC FOOT ULCERATION IN TYPES 1 AND 2 DIABETES

 ÀϹÝÀûÀ¸·Î Á¦2Çü ´ç´¢º´(T2D) ȯÀÚ°¡ Á¦1Çü ´ç´¢º´(T1D) ȯÀÚº¸´Ù ´ç´¢¹ß ±Ë¾ç(DFU)¿¡ °É¸± À§ÇèÀÌ ´õ Å©´Ù. ÀÌ·¯ÇÑ ³ôÀº ¹ß»ý·üÀÇ ÁÖ¿ä ¿øÀÎÀº ´ÙÀ½°ú °°´Ù; Á¦2Çü ´ç´¢º´ÀÌ ´õ ÈçÇÏ°Ô ¹ß»ýÇÑ´Ù. ºñ¸¸, ¸»ÃÊÇ÷°üÁúȯ(peripheral vascular disease), ½Å°æº´Áõ(neuropathy)°ú °°Àº À§Çè ¿äÀÎÀÌ µ¿¹ÝµÉ °¡´É¼ºÀÌ ³ô´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ¹ß ±Ë¾ç ¹ß»ý À§ÇèÀ» Áõ°¡½ÃŲ´Ù.

 Á¦1Çü ´ç´¢º´¿¡¼­´Â ¹ß ±Ë¾çÀÌ »ó´ëÀûÀ¸·Î ´ú ¹ß»ýÇÏÁö¸¸, ´ç´¢º´À» ¿À·¡ ¾Î¾Ò°Å³ª Ç÷´ç Á¶ÀýÀÌ ÀßµÇÁö ¾Ê¾Æ ´çÈ­Ç÷»ö¼Ò(HbA1C)°¡ ³ôÀº °æ¿ì¿¡´Â ¹ß»ýÇÒ ¼ö ÀÖ´Ù. µû¶ó¼­ Á¦1Çü°ú Á¦2Çü ´ç´¢º´ ¸ðµÎ¿¡¼­ ¹ß °ü¸®(foot care) ¹× Á¤±âÀûÀÎ Á¡°Ë(regular monitoring)ÀÌ ÇʼöÀûÀ̸ç, À̸¦ ÅëÇØ ¹ß ±Ë¾çÀ» ¿¹¹æÇϰí Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Ù.

PATHOPHYSIOLOGY OF DIABETIC FOOT ULCERS

1. ´ç´¢¹ß ±Ë¾çÀÇ ºÐ·ù
  • 1). ½Å°æº´Áõ¼º(Neuropathic), ÇãÇ÷¼º(Ischemic), ½Å°æÇãÇ÷¼º(Neuroischemic)À¸·Î ³ª´¶´Ù.
  • 2). Wagner ½Ã½ºÅÛ: DFUÀÇ ÁßÁõµµ¸¦ 1~5´Ü°è·Î ºÐ·ùÇϴ ü°è.
  • 3). ÅØ»ç½º ´ëÇÐ ½Ã½ºÅÛ(University of Texas System): Wagner ½Ã½ºÅÛÀÇ ÇѰ踦 º¸¿ÏÇÏ¿© Ç÷°ü »óÅ ¹× °¨¿° ¿©ºÎ±îÁö ¹Ý¿µÇÑ °³¼±µÈ ºÐ·ù ü°è(Box 1)
2. ´ç´¢º´°ú ½Å°æº´Áõ(Neuropathy)ÀÇ ¿ªÇÒ
  • 1). °¨°¢ ½Å°æº´ÁõÀº ´ç´¢º´ ȯÀÚ¿¡¼­aldose reductase¿Í sorbitol dehydrogenaseÀÇ ¹ßÇö Áõ°¡¸¦ À¯µµÇϸç, ÀÌ·Î ÀÎÇØfructose¿Í sorbitolÀÇ »ý¼ºÀÌ Áõ°¡ÇÏ°Ô µÈ´Ù. ÀÌ·Î ÀÎÇØ sorbitol°úfructose°¡ ÃàÀûµÇ¸ç ½Å°æ¼¼Æ÷ÀÇ »ïÅõ¾Ð ½ºÆ®·¹½º(osmotic stress)¸¦ À¯¹ßÇÏ¿©½Å°æ Àü´Þ ÀúÇϽÃŲ´Ù.
  • 2). AGEs (Advanced Glycation End Products)µµ ½Å°æ ¹× Á¶Á÷ ¼Õ»óÀ» °¡¼ÓÈ­ÇÑ´Ù.
  • 3). ÀÚÀ²½Å°æ°è ±â´ÉÀå¾Ö(autonomic dysfunction)·Î ÀÎÇØ ¶¡ ºÐºñ°¡ °¨¼ÒÇÏ¿©¹ßÀÌ °ÇÁ¶ÇØÁö°í ±Õ¿­(fissuring) ¹ß»ý À§Çè Áõ°¡
    -¿îµ¿ ½Å°æ(motor neuron) ÀÌ»óÀ¸·Î ±ÙÀ° À§Ãà(muscle wasting)°ú ¹ß º¯Çü(foot deformity)ÀÌ ¹ß»ýÇÏ¸é ¹ß¹Ù´Ú Æ¯Á¤ ºÎÀ§¿¡ ¾Ð·Â ÁýÁßÇÏ°Ô µÇ°í ±Ë¾ç ¹ß»ý À§Çè Áõ°¡ÇÑ´Ù.
3. ´ç´¢º´°ú »óó Ä¡À¯ Áö¿¬
  »óó Ä¡À¯ÀÇ Ãʱ⠴ܰ迡¼­ È£Áß±¸(neutrophil)´Â Á¤»óÀûÀ¸·Î °ú¸³¼º ºÐÀÚ¸¦ ¹æÃâÇÏ¿© ¿ÜºÎ º´¿ø±ÕÀ» Á¦°ÅÇϴµ¥, ÀÌ °úÁ¤Àº NETosis(È£Áß±¸ ¼¼Æ÷¿Ü µ£(neutrophil extracellular traps) Çü¼º±âÀü)¶ó°í ÇÑ´Ù. ±×·¯³ª ´ç´¢º´ ȯ°æ¿¡¼­´Â NETosis°¡ Á¶ÀýµÇÁö ¾Ê¾Æ ¿°Áõ ¹ÝÀÀÀÌ °úµµÇÏ°Ô È°¼ºÈ­µÇ¸ç, »çÀÌÅäÄ«Àΰú Ãʰú»êÈ­¹°(superoxide)ÀÇ °ú»ý¼ºÀÌ ¹ß»ýÇÏ¿© »óó Ä¡À¯°¡ Áö¿¬µÈ´Ù. ¶ÇÇÑ, °íÇ÷´ç(hyperglycemia)Àº AGEs(Advanced Glycation End Products)ÀÇ Çü¼ºÀ» À¯µµÇÏ¿© ÁÖ¿ä ´Ü¹éÁúÀÇ ±¸Á¶Àû¡¤±â´ÉÀû º¯È­¸¦ ÃÊ·¡ÇÑ´Ù. ±× °á°ú, »çÀÌÅäÄ«ÀÎÀÇ ¹æÃâÀÌ °úµµÇÏ°Ô Áõ°¡Çϰí, ÀÚ°¡ Áö¼ÓÀûÀÎ ¿°Áõ ¹ÝÀÀÀÌ À¯¹ßµÇ¸ç, ÀÌ´Â ¿°Áõ »óŸ¦ Àå±âÈ­ÇÏ°í ¼¼Æ÷ »ç¸ê(apoptosis)À» ÃËÁøÇÏ°Ô µÈ´Ù.
4. ¼¼Æ÷¿Ü±âÁú(ECM) º¯È­¿Í »óó ȸº¹ ÀúÇÏ
  ´ç´¢º´¿¡¼­´Â MMP(Matrix Metalloproteinase)¶ó´ÂÄݶó°Õ ºÐÇØ È¿¼Ò°¡ °úȰ¼ºÈ­µÇ¸é¼­ ³ôÀº ´Ü¹éÁú ºÐÇØ ȯ°æÀÌ Á¶¼ºµÇ°í, ±× °á°ú Äݶó°Õ ÇÔ·®ÀÌ °¨¼ÒÇÑ´Ù. ÀÌ·¯ÇÑ º¯È­·Î ÀÎÇØ ECM ±¸Á¶°¡ ºØ±«µÇ¸ç, »óó Ä¡À¯¸¦ È¿°úÀûÀ¸·Î Áö¿øÇÏÁö ¸øÇÏ´Â »óŰ¡ µÈ´Ù. ¶ÇÇÑ ¶ÇÇÑ, MMP Ȱ¼º Áõ°¡¿Í ÇÔ²² AGEsÀÌ ÃàÀûµÇ¸é¼­ FGF(Fibroblast Growth Factor)¹× TGF-¥â(Transforming Growth Factor-Beta)ÀÇ °¨¼Ò¸¦ ÃÊ·¡ÇÑ´Ù. ÀÌ´Â ¼¶À¯¾Æ¼¼Æ÷ÀÇ ¼¼Æ÷ »ç¸ê(apoptosis)À» À¯µµÇÏ¿© Äݶó°Õ ÇÔ·®À» ´õ¿í °¨¼Ò½ÃŰ´Â À¯»çÇÑ È¿°ú¸¦ ³ªÅ¸³½´Ù.
5. DFUÀÇ ÇÙ½É º´Å»ý¸®¿Í ¿¬±¸ Àü¸Á
  ´ç´¢º´¼º ½Å°æº´Áõ(Neuropathy)°ú ¹Ì¼¼Ç÷°üÁúȯ(Microvascular disease)ÀÌ DFU ¹ß»ý¿¡ Áß½ÉÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù. ½ÅÀå Áúȯ, ¸é¿ª°è ÀÌ»ó, Àν¶¸° ´ë»ç Àå¾Ö µîµµ DFU ÁøÇà¿¡ ±â¿©ÇÑ´Ù. ´ç´¢º´¼º ½Å°æº´ÁõÀÇ ±âÀüÀº ¾ÆÁ÷ ¿ÏÀüÈ÷ ¹àÇôÁöÁö ¾Ê¾ÒÀ¸¸ç, ÇâÈÄ ³ëÀÎ ´ç´¢ ȯÀÚ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î Áø´Ü ¹× Ä¡·á¹ý ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù.

A PREVENTIVE, DIAGNOSTIC, AND THERAPEUTIC PLAN FOR HEALING

  ±Þ¼º »óó°¡ Á¤»óÀûÀÎ Ä¡À¯ °úÁ¤¿¡¼­ ¹þ¾î³ª¸é ¸¸¼º »óó·Î ¹ßÀüÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ±¹¼Ò °¨¿°¿¡¼­ ½ÃÀÛÇØ °¨¿°ÀÌ È®»êµÇ°í »óó°¡ ±í¾îÁö¸ç, ÆÐÇ÷Áõ, »çÁö À§Çù °¨¿°, Àý´Ü, ½ÉÁö¾î »ç¸Á±îÁö À̸¦ ¼ö ÀÖ´Ù.
1. "Ä¡À¯ °èȹ(Plan for Healing)"ÀÇ Á߿伺:
  "Ä¡À¯ °èȹ"Àº öÀúÇÑ º´·Â Á¶»ç¿Í ½Åü °ËÁø, °ü·ÃµÈ Ç÷¾× °Ë»ç ¹× Áø´Ü °úÁ¤, ȯÀÚÀÇ ½É¸®»çȸÀû »óÅ ¹× Ä¡·á ¸ñÇ¥ Æò°¡, ±×¸®°í »óó Æò°¡·Î ½ÃÀ۵ȴÙ. ÀÌÈÄ ¿¹¹æ, Áø´Ü ¹× Ä¡·á¿Í °ü·ÃµÈ ±Ù°Å ±â¹Ý ÀÓ»ó Ä¡·á ÁöħÀ» Àû¿ëÇϰí, °ü·Ã ÁúȯÀ» °ü¸®Çϸç, ÀûÀýÇÑ ÀÇÇÐÀû ¹× ¿Ü°úÀû Ä¡·á °èȹÀ» ¼ö¸³Çϰí, ȯÀÚ ¹× °¡Á· ±³À°À» º´ÇàÇÑ´Ù.
2. Total Contact Casting (TCC) Ä¡·á:
  TCC´Â Wagner µî±Þ I ¹× IIÀÇ ´ç´¢º´¼º Á·ºÎ±Ë¾ç Ä¡·áÀÇ Ç¥ÁØ ¹æ¹ýÀ¸·Î, Á¶Á÷ ȸº¹¿¡ ÀûÇÕÇÑ È¯°æÀ» Á¶¼ºÇÔÀ¸·Î½á »óó Ä¡À¯¸¦ ÃËÁøÇÏ´Â µ¥ µµ¿òÀ» ÁØ´Ù. TCCÀÇ ÁÖ¿ä ¸ñÇ¥´Â ±Ë¾ç ºÎÀ§ÀÇ ¾Ð·ÂÀ» ºÐ»ê½ÃŰ´Â °ÍÀ¸·Î, À̸¦ ÅëÇØ ¿°ÁõÀ» ÁÙÀ̰í Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÏ¸ç °Ç°­ÇÑ »õ Á¶Á÷ÀÇ Çü¼ºÀ» ÃËÁøÇÑ´Ù. ¶ÇÇÑ, ÀÌ ¼®°íºØ´ë´Â ¹ß°ú ¹ß¸ñÀ» ¾ÈÁ¤ÀûÀ¸·Î ÁöÁöÇÏ¿© Ãß°¡ ¼Õ»óÀ» ¿¹¹æÇÏ°í ¿Ã¹Ù¸¥ Ä¡À¯¸¦ µ½´Â´Ù.

PATIENT ASSESSMENT

1. ³ëÀΠȯÀÚÀÇ »óó Ä¡·á¸¦ À§ÇÑ º´·Â Á¶»ç
  º´·ÂÁ¶»ç´Â ÀÇÇÐÀû, ¿Ü°úÀû, ¾à¸®ÇÐÀû ¿ä¼Ò¸¦ Æ÷ÇÔÇϸç, À̸¦ ÅëÇØ ȯÀÚÀÇ Ä¡À¯ ´É·ÂÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Ù. »óó Ä¡·áÀÚ´Â Áúº´, º¹¿ë ÁßÀÎ ¾à¹°, ÀÌÀü ¼ö¼ú ÀÌ·ÂÀÌ »óó Ä¡À¯ °á°ú¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÀÌÇØÇÏ°í °¨¿°À» Á¶±â¿¡ ¹ß°ßÇϱâ À§ÇØ ÁÖÀÇÇØ¾ß ÇÑ´Ù. À̿ܿ¡µµ ÀÎÁö ±â´É, ¿µ¾ç »óÅÂ, ±â´ÉÀû »óÅ µîÀÇ ¿ä¼Òµµ °í·ÁÇØ¾ß ÇÑ´Ù.
2. ³ëÀΠȯÀÚ Æò°¡ ½Ã °í·ÁÇØ¾ß ÇÒ ÁÖ¿ä Áú¹®
  • 1). Is there an acute component to the wound?
  • 2). Is there a chronic component to the wound?
  • 3). Are there signs and symptoms of infection?
  • 4). Are there signs and symptoms of ischemia?
  • 5). Are there signs and symptoms of neuropathy?
  • 6). What is the cognitive and psychosocial status of the patient?
  • 7). Can this wound be healed, and is this wound considered palliative?
3. ½Åü °Ë»ç ¹× Áø´Ü °Ë»ç
  ½Åü °Ë»ç´Â ´ÙÀ½°ú °°Àº ¿ä¼Ò¸¦ Æ÷ÇÔÇØ¾ß ÇÑ´Ù: ¸Æ¹Ú ÃËÁø(palpation of pulses): Ç÷¾× ¼øÈ¯ »óÅ ȮÀÎ, ¸ð¼¼Ç÷°ü ÀçÃæÀü ½Ã°£(capillary refill time): Ç÷°ü ±â´É Æò°¡, ¸ð³ëÇʶó¸àÆ® °Ë»ç¸¦ ÅëÇÑ °¨°¢ Æò°¡(monofilament test for sensation): ½Å°æ ¼Õ»ó ¿©ºÎ È®ÀÎ, »óóÀÇ ÇüÅ ¹× Å©±â ÃøÁ¤(description and measurement of the wound), »óó°¡ »À±îÁö µµ´ÞÇß´ÂÁö È®ÀÎ(probing the wound to bone)
Áø´Ü °Ë»ç´Â ´ÙÀ½°ú °°ÀÌ ÁøÇàÇÒ ¼ö ÀÖ´Ù.
  • 1). Ç÷¾× °Ë»ç: ÀüÇ÷±¸°Ë»ç(CBC), Ç÷¾×È­Çа˻ç(serum chemistries, ¿¹: Ç÷û ¾ËºÎ¹Î ¹× HbA1C ÃøÁ¤
  • 2). ºñħ½ÀÀû Ç÷°ü Æò°¡: ¸Æ¹Ú ¿ëÀû ±â·Ï(pulse volume recordings), °æÇÇ»ê¼ÒºÐ¾Ð(transcutaneous oxygen tension, TcPO2) ÃøÁ¤, ±âŸ Ç÷°ü °Ë»ç(Áö¿ª Ç÷°ü °Ë»ç½ÇÀÇ Áø´Ü Àåºñ¿¡ µû¶ó Ãß°¡ °¡´É)
  • 3). ¹ß¸ñ»ó¿ÏÁö¼ö(ABI, Ankle-Brachial Index) ÃøÁ¤: ±×·¯³ª ³ëÀΠȯÀÚ´Â µ¿¸ÆÀÇ ¼®È¸È­·Î ÀÎÇØ Ç÷°üÀÌ ºñ¾ÐÃ༺(non-compressible)ÀÎ °æ¿ì°¡ ¸¹¾Æ, ABI °á°ú°¡ Á¤È®ÇÏÁö ¾ÊÀ» ¼ö ÀÖÀ½
  • 4). °ñ¼ö¿°(osteomyelitis) Áø´Ü: MRI°¡ ÃÖ¼±ÀÇ ¿µ»óÇÐÀû Áø´Ü ¹æ¹ý, º¸´Ù Á¤È®ÇÑ Áø´Ü°ú Ç×»ýÁ¦ Ä¡·á ¹æÇâ ¼³Á¤À» À§ÇØ »À »ý°Ë(bone biopsy)Ãßõ

THE FUTURE

  ¸¹Àº ȯÀÚµéÀº »õ·Î¿î »óó¸¦ ¹ß°ßÇÏ¸é  ¸ÕÀú 1Â÷ Áø·áÀǸ¦ ã±â ¶§¹®¿¡, Á¤È®ÇÑ Áø´ÜÀ» ³»¸®°í »óó Àü¹®ÀÇ·ÎÀÇ ÀûÀýÇÑ ÀÇ·Ú°¡ ÀÌ·ç¾îÁú ¼ö ÀÖµµ·Ï °³¼±µÈ Áø·á ü°è°¡ ¿ä±¸µÈ´Ù. ¶ÇÇÑ, ´ç´¢¹ß ±Ë¾çÀ» Á¶±â¿¡ ½Äº°Çϰí Ä¡À¯ °¡´É¼ºÀ» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ÀÇ ÁøÇàÀÌ ¿ä±¸µÈ´Ù. ¶ÇÇÑ, ½º¸¶Æ®ÆùÀ» Ȱ¿ëÇÑ »óó Ä¡·á ±³À° ÀÚ·á°¡ ÇÊ¿äÇÏ´Ù.
Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ ȯÀÚ°¡ ±ÞÁõÇÏ´Â ¸¸Å­, ¿¹¹æ, Ä¡À¯ ¹× ÇÕº´Áõ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ±Û·Î¹ú ±³À°ÀÌ ÇʼöÀûÀ̸ç, ƯÈ÷ ´ÙÇÐÁ¦Àû Á¢±Ù ¹æ½ÄÀº ¸Å¿ì Áß¿äÇÏ´Ù°í ÇϰڴÙ.

À̸§ ÆÐ½º¿öµå
ºñ¹Ð±Û (üũÇÏ¸é ±Û¾´À̸¸ ³»¿ëÀ» È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.)
¿ÞÂÊÀÇ ±ÛÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä.